An observational study in Overweight, sponsored by Certmedica International GmbH. Completed at 1 site in Germany. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-27.
Sponsored by Certmedica International GmbH · Observational
Among 149 studies in Overweight with a site in Germany — 38 open to participants now, 60 under way, 34 of them phase 3. Overweight · Germany.
Among the 149 studies in Overweight with a site in Germany, this one is one of 25 that started in 2025, is one of 8 observational ones, and was the 128th registered.
3,599 studies on the registry are indexed under Overweight; 852 are open to participants now.
Browse Overweight studies →38 of the 149 studies in Overweight with a site in Germany are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Germany, United States, Brazil and 7 more countries
Novo Nordisk A/S · Sites in Germany
Boehringer Ingelheim · Sites in Germany
German Diabetes Center · Sites in Germany
Buchinger Wilhelmi Development & Holding GmbH · Sites in Germany
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 529 Overweight studies recruiting now, 158 (30%) set no upper age limit and 343 (65%) stop at 75 or younger; 62 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
149 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 26 · Phase 2 10 · Phase 3 48 · Phase 4 6
First in 2004; this study’s year is marked. 25 started in 2025.
This study's enrollment of 41 is below the median of 154 across 424 observational studies indexed under Overweight.
Median enrollment 137 across the 141 interventional studies, 275 across the 8 observational. Of the 81 that completed or were terminated, 13 (16%) have results posted.
This tab as a report to print or save as PDF → With an account.
97 of 149 have an industry lead sponsor. The 10 most frequent:
Certmedica International GmbH is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
Certmedica International GmbH has 4 studies filed under Overweight — fewer than ten, so there is no comparison to draw.
24 of the studies in Overweight with a site in Germany that are under way reach primary completion within a year, 12 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914895Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) Compared With Placebo in Adults With Type 1 Diabetes and Obesity or Overweight | 2026-11 |
| NCT06858839Phase 3AmgenEvaluation of Maridebart Cafraglutide in Adult Participants Without Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
Among the 149 studies in Overweight with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
As a combination of medical products (mBCA scale, mBCA standing aid, length measuring rod and cloud-based software), the seca mBCA 555 makes it possible to determine nutritional status, energy consumption and body water distribution. For this purpose, weight, height and bioimpedance data are measured and further body composition parameters are determined. In addition, changes in muscle mass and fat mass resulting from physical training can be assessed. It is a class IIa medical device.
The L112 product range serves as a lipid binder for weight reduction and weight maintenance with an accompanying LDL cholesterol-lowering effect. It is a class III medical device.
The aim of this study is to explore which early changes in body composition and other health parameters accessible by bioimpedance measurement can be detected with the mBCA 555 measurement method when taking the L112 product series even before weight reduction.
If it were possible to detect changes in health parameters that can be recorded with the mBCA 555 at an early stage while taking the L112 product range, a strategy could be developed to motivate users. In the successful treatment of obesity, patient compliance and motivation are crucial due to the necessary dietary and lifestyle changes. Early successes or indications of a good development of the mBCA health parameters, which are visible even before a relevant change in weight, can serve as a motivational aid and lead to better success in weight reduction. This exploratory study aims to identify these parameters as a basis for further clinical studies.
Research question:
What changes in body composition and other health parameters accessible through bioimpedance measurement can be measured when taking the L112 product range before weight loss?
Aschaffenburg and surrounding area
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
For weight control (participants with BMI \< 25), the dose is reduced to 2 tablets daily
Other: formoline L112 EXTRA
For weight reduction (participants with BMI ≥ 25): 2 x 2 tablets with the two meals with the highest fat content
Other: formoline L112 EXTRA
Taking formoline L112 EXTRA (750 mg tablets) for a duration of 12 weeks: For weight reduction (participants with BMI ≥ 25): 2 x 2 tablets with the two meals with the highest fat content For weight control (participants with BMI \< 25), the dose is reduced to 2 tablets daily.
BMI (Body-Mass-Index)
Measurement with seca mBCA 555, unit kg/m2
Time frame: 12 weeks
Body weight
Measurement with seca mBCA 555, unit kg
Time frame: 12 weeks
FMI (Fat-Mass-Index)
Measurement with seca mBCA 555, unit kg/m2
Time frame: 12 weeks
FM% (fat-mass percentage)
Measurement with seca mBCA 555, unit %
Time frame: 12 weeks
FFMI (fat-free-mass-index)
measured with seca mBCA bioimpedance scale, unit kg/m2
Time frame: 12 weeks
SSM (Skeletal muscle mass)
measured with seca mBCA bioimpedance scale, unit kg
Time frame: 12 weeks
SMI (Skeletal muscle index)
measured with seca mBCA bioimpedance scale, unit kg/m2
Time frame: 12 weeks
Skeletal muscle mass depending on age
measured with seca mBCA bioimpedance scale, unit kg
Time frame: 12 weeks
Phase angle
measured with seca mBCA bioimpedance scale, unit Degree
Time frame: 12 weeks
Visceral fat
measured with seca mBCA bioimpedance scale, unit litre
Time frame: 12 weeks
Skeletal muscle mass index of the extremities
measured with seca mBCA bioimpedance scale, unit kg/m2
Time frame: 12 weeks
Waist circumference
measured manually with meassuring tape, unit cm
Time frame: 12 weeks
Body Composition Chart
produced by seca analytics from seca mBCA bioimpedance measurements of fat mass and skeletal muscle mass.
Time frame: 12 weeks
Segmental skeletal muscle mass distributed over the 5 segments: Arm right, Arm left, torso, leg right, leg left
measured with seca mBCA bioimpedance scale, unit kg
Time frame: 12 weeks
TBW (total body water)
measured with seca mBCA bioimpedance scale, unit litre
Time frame: 12 weeks
ECW (extracellular water)
measured with seca mBCA bioimpedance scale, unit litre
Time frame: 12 weeks
Water ratio ECW/TBW
calculated by seca analytics from measured with seca mBCA bioimpedance scale of ECW (extracellular water) and TBW (total body water)
Time frame: 12 weeks
Bioelectrical impedance vector analysis
produced by seca analytics from seca mBCA bioimpedance scale measurements concerning body cell mass and hydration status
Time frame: 12 weeks
TRU Body Score
calculated by seca analytics from seca mBCA bioimpedance scale measurements of muscle and fat mass, reflecting training status
Time frame: 12 weeks
Ran from Apr 2025 to primary completion in Feb 2026, 10 months.
Of 169 observational studies under Overweight, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 91. This study's 10 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Certmedica International GmbH